Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.30 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.30 |
| ▸ | AKT1 | P31749 | 2/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371049 | 0.88 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTCYP2C9MEN1 | |
| SCHEMBL12371037 | 0.75 | CYP2C9 (0.48) | ALDH1A1LMNAMAPTCYP2C9MEN1 | |
| SCHEMBL12371039 | 0.74 | CYP2C9 (0.36) | ALDH1A1LMNAMAPTCYP2C9MEN1 | |
| SCHEMBL2277758 | 0.74 | CYP1A2 (0.41) | ALDH1A1LMNAMAPTCYP2C9KMT2A | |
| SCHEMBL2273779 | 0.74 | CYP1A2 (0.41) | ALDH1A1LMNAMAPTCYP2C9KMT2A | |
| SCHEMBL2277755 | 0.74 | CYP1A2 (0.41) | ALDH1A1LMNAMAPTCYP2C9KMT2A | |
| SCHEMBL2273782 | 0.74 | CYP1A2 (0.41) | ALDH1A1LMNAMAPTCYP2C9KMT2A | |
| SCHEMBL2273773 | 0.74 | CYP1A2 (0.41) | ALDH1A1LMNAMAPTCYP2C9KMT2A | |
| SCHEMBL15744346 | 0.74 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTCYP2C9MEN1 | |
| SCHEMBL12371053 | 0.73 | RAB9A (0.41) | ALDH1A1LMNAMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999123-B2 | 2-oxetanone derivative and process for production thereof | JNC CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | OGDH, OXGR1, OXER1 | ALDH1A1 28/4885LMNA 3383/4885MAPT 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.